by Andrew Thurston – Boston University – The Brink –
It’s a disease that can literally take your breath away—and there’s no cure. As pulmonary fibrosis progresses, it causes scarring in the lungs, making it harder and harder to absorb oxygen into the bloodstream. For many of those with the most common form of the disease, idiopathic pulmonary fibrosis, life expectancy is less than five years.
A new collaboration between the global biopharma giant GSK and researchers from the Center for Regenerative Medicine of Boston University and Boston Medical Center (CReM) could bring hope to the millions around the world with the relentless condition, as well as other lung diseases.
